United States: Capitol Hill Healthcare Update - October 2, 2017

Alexander, Murray Seek Health Law Stabilization Agreement

With congressional Republicans' efforts to repeal the Affordable Care Act (ACA) on hold at least for now, the bipartisan leaders of the Senate HELP Committee are seeking to rekindle their work to shore up the health law's troubled individual marketplace.

Committee Chairman Lamar Alexander (R-Tenn.) said he hoped to be able to announce an agreement as soon as this week with the top panel Democrat, Sen. Patty Murray (D-Wash.). The senators have been discussing a deal that would include locking in cost-sharing payments to insurers while granting states flexibility to try to lower consumers' insurance costs.

Even if the two senators reach an agreement, it is not clear it would have sufficient bipartisan support to receive the needed 60 votes in the Senate or win approval in the more conservative House.

Alexander and Murray halted their negotiations last month while Senate Republicans struggled and ultimately failed to gain votes for their latest ACA replacement legislation by Sens. Lindsey Graham (R-S.C.) and Bill Cassidy (R-La.).

Republicans Hope to Revive ACA Repeal Efforts Later

Like the victim of the Black Plague in "Monty Python and the Holy Grail," congressional Republicans' efforts to replace the ACA are not quite dead.

Despite two failed Senate attempts in July and last month, some Republicans say they want the option to try again.

The GOP's previous efforts at repealing the ACA have been with special legislation called "reconciliation," which prevents a Senate filibuster and allows the bill to be approved with 50 Senate votes instead of the usual 60. But the reconciliation bill Republicans had been using in recent months expired September 30, the end of the 2017 federal fiscal year.

To authorize a new reconciliation bill, Congress needs to approve a separate fiscal 2018 budget resolution. Republicans appear on track to do that in the coming weeks. While the GOP had planned to use that reconciliation legislation as a vehicle for tax reform, it could be expanded to make room for tax reform and ACA repeal.

A more likely scenario is that Congress keeps the fiscal 2018 reconciliation legislation for taxes and instead targets next spring, when lawmakers would begin consideration of the fiscal 2019 budget, for an ACA reconciliation bill.

Still, whichever timeline Republicans use, it is not clear the intra-party divisions that have undermined the GOP's efforts thus far will be any more successful in the future. Indeed, the Republican candidate currently expected to win a special Senate election in Alabama says he would have opposed the ACA repeal bill backed by GOP leaders last month.

Verma, Gottlieb Seen as Leading Candidates for HHS

Two Trump administration healthcare leaders who have already been through Senate confirmation are among the leading contenders to replace the former Secretary of the U.S. Department of Health and Human Services (HHS) Tom Price, who resigned on Friday.

Before becoming administrator of the Centers for Medicare & Medicaid Services (CMS) in March, Seema Verma advised several states on their Medicaid expansion plans, including Indiana, where she worked with then-Gov. Mike Pence. She also has been active on Capitol Hill as an administration liaison lobbying congressional Republicans to repeal the ACA.

Scott Gottlieb held several federal healthcare positions prior to becoming FDA commissioner in May. A physician, Gottlieb earlier served as the FDA's deputy commissioner and as a senior advisor to a previous FDA commissioner, and separately as a senior advisor to a previous CMS administrator.

Although both Verma and Gottlieb are only months into their current jobs, each are known quantities who have recently been confirmed by the Senate, giving both an advantage over other potential candidates.

The White House has not announced a timeline for choosing Price's successor.

House, Senate Committees to Vote on CHIP Renewal This Week

Two congressional committees are slated to vote this week on separate legislation to extend the Children's Health Insurance Program (CHIP).

Federal funding for CHIP expired Saturday, the start of the 2018 federal fiscal year. But most states say they have money to operate the program well into next year.

The House Energy and Commerce Committee and the Senate Finance Committee will meet separately Wednesday to consider different versions of the CHIP renewal bills.

The bipartisan leadership of the Senate panel – Sens. Orrin Hatch (R-Utah) and Ron Wyden (D-Ore.) – last month announced they had reached an agreement on a five-year CHIP renewal. Their bill also would wind down an ACA funding boost over three years – a formula that won widespread praise from providers.

House committee staff worked this weekend on the scope of their as-yet-unreleased bill, including how long to renew the program, how to phase down the higher federal match and what other healthcare funding will be trimmed to offset CHIP funding. Reauthorization of a federal program for community health centers, which provide care for about 24 million people in medically underserved areas, is expected to be included in the House CHIP bill.

Senate Democrats Demand Allergan-Tribe Probe

Four Senate Democrats are calling on the Judiciary Committee to investigate Allergan's attempt to block the review of some of its drug patents by selling them to a Native American tribe in New York.

The senators criticized the "blatantly anti-competitive attempt" to sell the patents to the Saint Regis Mohawk Tribe, saying the deal raises significant patent law and anti-competitive implications that the committee should address.

The letter was written to committee Chairman Charles Grassley (R-Iowa) by Sens. Maggie Hassan (D-N.H.), Sherrod Brown (D-Ohio), Robert Casey (D-Pa.), and Richard Blumenthal (D-Conn.).

Mylan had initiated a Patent and Trademark Office (PTO) administrative challenge to Allergan's Restasis eye drug, which earned $1.5 billion last year. But Allergan then sold the Restasis patent to the tribe for a one-time payment of $13.8 million and $15 million annually in royalties in return for exclusive licensing. The tribe last month called on PTO to dismiss the Mylan challenge, saying its sovereign status effectively shields it from the agency's jurisdiction.

Gottlieb to Testify at 'Right-to-Try' Hearing

The House Energy and Commerce Health Subcommittee on Tuesday will hold a hearing on proposals that would give terminally ill patients wider access to prescription drugs and medical devices that have not yet won FDA approval.

Among the scheduled witnesses is FDA Commissioner Scott Gottlieb, who sounded caution in limited comments earlier this year on loosening the agency's expanded access program with so-called "right-to-try" legislation. By contrast, Vice President Pence earlier this year publicly endorsed the legislative effort.

The subcommittee announced it will consider two similar bills: House legislation that would grant wider access to drugs and devices, and Senate-approved legislation that would only apply to drugs. The House bill, introduced by Rep. Morgan Griffith (R-Va.), would permit access to treatments beyond existing compassionate use programs – even for drugs and devices that have not completed a clinical trial. The more narrowly tailored bill, introduced by Sen. Ron Johnson (R-Wis.), would only apply to prescription drugs.

Senate Opioid Hearing to Feature Top HHS Officials

Leading healthcare officials from the federal government will testify Thursday at a Senate HELP Committee hearing about Washington's response to the opioid crisis.

The committee will review implementation of last year's Comprehensive Addiction and Recovery Act, which authorizes $181 million to support opioid prevention and treatment programs. The panel will discuss implementation of the 21st Century Cures Act, which included $1 billion in grants to states to combat opioid abuse.

Witnesses at the hearing include FDA Commissioner Scott Gottlieb, NIH Director Francis Collins, CDC Director Brenda Fitzgerald and Elinore McCance-Katz, an assistant secretary at the Substance Abuse and Mental Health Services Administration.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

    Disclaimer

    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

    Registration

    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

    Cookies

    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

    Links

    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

    Mail-A-Friend

    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

    Emails

    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

    Security

    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions